Mike Hollan

The ROGUE device is being developed thanks to a $34.9 million grant from ARPA-H.

Daiichi Sankyo’s head of US oncology business discusses the company’s first DTC television campaign for Enhertu.

Immorta Bio’s president discusses the company’s work with age-related diseases.

The Astellas chief commercial officer discusses the impact that the increase in global and local connectivity has had on commercialization, among other trends.

CSL and Artcurus announced the results of a study on the self-amplifying RNA vaccine.

Corcoran is using her family’s personal story with the disease to promote awareness.

Murphy previously worked at the Biotechnology Innovation Organization as its chief policy officer.

The program, Rx-Performance, will be available starting in January of next year.

The anti-obesity drug maker is raising awareness about the struggle that constant thoughts about food can have on people trying to manage their weight.

The Calliditas Therapeutics CEO discusses her transition from a banker/investor to CEO of a pharma company.

The Octave Bioscience CEO discusses leading the company through commercialization and expansion.

Atossa Therapeutics’ CEO discusses how the new draft guidance will change the way that many women receive their breast exam results.

The drug is approved for newly diagnosed patients not eligible for transplant and is to be used in combination with standard-of-care treatment.

The foundation is focused on preventing teen and young adult suicide.

Dr. Cherukuri discusses the impact of Apple’s new AirPods and their ability to be used as hearing aids.

Truxal discusses Exact Science’s first Spanish language TV commercial and campaign for Cologuard.

The program is aimed at raising funds for children with cancer and blood disorders.

The service will provide compounding pharmacy services to healthcare providers.

Spector discusses his company’s goal of fighting inflammation without hurting the immune system.

The campaign is based on a messaging promoting an embrace of aging.

Multi-region clinical trials can provide for varied results, but may not paint a full picture for a specific population.

The Apple AirPods 2 will include software enabling hearing aid services.

The app will work alongside prescription drug treatment Flexilev.

To improved facilities will produce ingredients used in Alzheimer’s medications.

These services will help alleviate the impact of contraceptive deserts in the state.

Users of the platform will have access to Kyzatrex.

The company will begin investigating the effectiveness of TCP008 for the highly infectious disease.

This is the second biosimilar that the company is offering to its customers at this price.

The device is part of the growing home health monitoring trend.

Customers will be able to file one claim across multiple products from the company.